Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte‐rich hepatocellular carcinoma
Open Access
- 9 September 2021
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 9 (9) , e04764
Abstract
Our pathological study of a case of poorly differentiated lymphocyte‐rich hepatocellular carcinoma suggested that immune checkpoint inhibitor may be an effective therapy. The histological type is an important factor in determining treatment choices.Keywords
This publication has 28 references indexed in Scilit:
- Lymphoepithelioma-like Hepatocellular CarcinomaAmerican Journal of Surgical Pathology, 2015
- Lymphoepithelioma-like hepatocellular carcinoma: Case report and review of the literatureWorld Journal of Gastroenterology, 2015
- Characterization of Inflammatory (Lymphoepithelioma-like) Hepatocellular Carcinoma: A Study of 8 CasesArchives of Pathology & Laboratory Medicine, 2014
- Lymphoepithelioma-like hepatocellular carcinoma: a case report and a review of the literatureWorld Journal of Surgical Oncology, 2013
- Hepatocellular carcinoma with massive lymphoid infiltration: A regressing phenomenon?Pathology - Research and Practice, 2009
- Lymphoepitelioma-like hepatocellular carcinoma: A case report and a review of the literatureWorld Journal of Gastroenterology, 2008
- Hepatocellular Lymphoepithelioma-Like Carcinoma Associated with Epstein Barr VirusDiagnostic Molecular Pathology, 2004
- Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltrationHepatology, 1998
- The Role of Epstein-Barr Virus in Lymphoepithelioma-like CarcinomasAmerican Journal of Clinical Pathology, 1995
- Lymphoepithelioma of the nasopharynxThe Laryngoscope, 1982